For DS-TB, BPaMZ successfully met the primary efficacy endpoint of sputum culture conversion. The regimen did not meet the key secondary efficacy endpoint due to adverse events resulting in treatment withdrawal. Our study demonstrated the potential for...
In 1948, the pioneering study that introduced streptomycin as the first treatment for tuberculosis (TB) was published, but the rapid onset of drug-resistant strains restricted the long-term benefit of streptomycin monotherapy.1 This led to the explorat...
The constant transformation of SARS-CoV-2 poses considerable challenges for COVID-19 vaccine programmes. Since it was first detected in August, 2023, the SARS-CoV-2 omicron subvariant BA.2.86, and in particular the sublineage JN.1, have rapidly spread ...
Compared with other SARS-CoV-2 variants, BA.2.86 and the JN.1 sublineage were less sensitive to vaccine-induced immune protection from the XBB.1.5 updated COVID-19 vaccine; however, we found no evidence that infection with BA.2.86 or JN.1 resulted in i...
The Pan-Lassa RDT is not currently recommended as a diagnostic or screening tool for suspected Lassa fever cases. Marked improvement in sensitivity and user friendliness is needed for the RDT to be adopted clinically. There remains an urgent need for b...
Lassa virus (LASV) is a high-consequence pathogen endemic to west Africa that causes annual outbreaks with substantial mortality. Besides transmission from the rodent reservoir to humans, human-to-human transmission can occur through contact with blood...
With two endorsed and prophylactic vaccines against Zaire ebolavirus (referred to hereafter as EBOV), the number of individuals vaccinated against EBOV worldwide is estimated to range between 500 000 and 1 000 000 individuals, increasing with every ren...
Although several countries have adopted a single-dose human papillomavirus (HPV) vaccination strategy, many other countries continue to include multiple doses in their vaccination programmes. There are ethical reasons to transition to a single-dose str...
Syphilis is a major global cause of fetal loss, stillbirth, neonatal death, and symptomatic disease in neonates and infants.1,2 In 2020, the global incidence of congenital syphilis was 425 cases per 100 000 livebirths, 8·5 times higher than elimination...
Antimicrobial resistance in Neisseria gonorrhoeae is an urgent global health threat. Ceftriaxone is the only remaining option for empirical monotherapy of gonococcal infections. The prevalence of ceftriaxone resistance in N gonorrhoeae is highest in th...
Antimicrobial resistance in Neisseria gonorrhoeae is an urgent global health threat. Ceftriaxone is the only remaining option for empirical monotherapy of gonococcal infections. The prevalence of ceftriaxone resistance in N gonorrhoeae is highest in th...
All tested dosing regimens blocked some infections to a similar degree. Improved vaccine efficacy in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation.
All tested dosing regimens blocked some infections to a similar degree. Improved vaccine efficacy in participants infected during vaccination could suggest new strategies for highly efficacious malaria vaccine development and implementation.
Malaria remains one of the most important parasitic diseases worldwide, with an estimated 249 million cases and 608 000 deaths in 2022.1 In July, 2022, the world's first malaria vaccine, RTS,S/AS01, was prequalified by WHO, paving the way for Gavi and ...
Malaria remains one of the most important parasitic diseases worldwide, with an estimated 249 million cases and 608 000 deaths in 2022.1 In July, 2022, the world's first malaria vaccine, RTS,S/AS01, was prequalified by WHO, paving the way for Gavi and ...
Ferrés M, Martínez-Valdebenito C, Henriquez C, et al. Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study. Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7—In ...